Lantheus Holdings

Lantheus Holdings develops, manufactures and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. The company's products include: DEFINITY, which is an ultrasound contrast imaging agent and is indicated for use in patients with suboptimal echocardiograms; TechneLite, which is a self-contained system or generator of Technetium, a radioactive isotope with a six hour half-life, used by radiopharmacies to prepare various nuclear imaging agents; and Xenon Xe 133 Gas, which is a radiopharmaceutical gas that is inhaled and used to assess pulmonary function and also to image cerebral blood flow.
  • TickerLNTH
  • ISINUS5165441032
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States
 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that data from the piflufolastat F 18 (formerly known as 18F-DCFPyL) CONDOR pivotal trial will be presented at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. Dr. Steven Rowe, Associate Professor of Radiology and Radiological Science at Johns...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021. The presentation will be made available for the duration of conference. Details fo...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Confe...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Thursday, June 3. To access a live webcast of the presentation, please visit the section of the Company’s website at ....

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its first quarter ended March 31, 2021. The Company’s worldwide revenue for the first quarter of 2021 totaled $92.5 million, compared with $90.7 million for the first quarter of 2020, representing an increase of 2.0% from the prior year period. The Company’s first quarter 2021 net income w...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that data from the piflufolastat F 18 (formerly known as 18F-DCFPyL) CONDOR pivotal trial will be presented at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting. Dr. Steven Rowe, Associate Professor of Radiology and Radiological Science at Johns...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today that the U.S. Food and Drug Administration (FDA) has approved PYLARIFY, an F 18-labeled prostate-specific membrane antigen (PSMA) targeted positron emission tomography (PET) imaging agent to identify suspected metastasis or recurrence of prostate cancer. PYLARIFY is the first and only...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, ...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced today a poster presentation featuring data from the Company’s Phase 3 CONDOR study at the upcoming 2021 American Society for Clinical Oncology (ASCO) Virtual Meeting, which will be held from June 4-8, 2021. The presentation will be made available for the duration of conference. Details fo...

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Holdings to Present at the Jefferies Virtual Healthcare Confe...

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today announced Mary Anne Heino, President and Chief Executive Officer, and Bob Marshall, Chief Financial Officer and Treasurer, will present at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Thursday, June 3. To access a live webcast of the presentation, please visit the section of the Company’s website at ....

 PRESS RELEASE
LNTH Lantheus Holdin... (Health Care)

Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results

NORTH BILLERICA, Mass.--(BUSINESS WIRE)-- (NASDAQ: LNTH) (Lantheus), an established leader and fully integrated provider of innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, today reported financial results for its first quarter ended March 31, 2021. The Company’s worldwide revenue for the first quarter of 2021 totaled $92.5 million, compared with $90.7 million for the first quarter of 2020, representing an increase of 2.0% from the prior year period. The Company’s first quarter 2021 net income w...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch